Acute onset of ulcerative colitis during chemoradiotherapy for anaplastic lymphoma kinase-positive lung adenocarcinoma

Kohei Fujita¹, Yoshinori Mizumoto², Koki Moriyoshi³, Norio Araki⁴ & Tadashi Mio¹

¹Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
²Division of Gastroenterology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
³Division of Clinical Pathology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
⁴Division of Radiation Oncology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Keywords
Chemoradiotherapy, chemotherapy, lung adenocarcinoma, non-small cell lung cancer, ulcerative colitis.

Abstract
We report a case of acute onset of ulcerative colitis (UC) during chemoradiotherapy in a patient with anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma. A 46-year-old male patient with an abnormal chest shadow was referred to our hospital. He was diagnosed with lung adenocarcinoma, clinical stage T1aN3M0 and stage IIIB. Concurrent chemoradiotherapy was selected for his initial therapy. After two cycles of cisplatin and vinorelbine administration, he experienced persistent diarrhoea and anorexia. Findings of the colonoscopy revealed a pancolitis type of UC. After discontinuation of chemotherapy, oral administration of mesalazine was initiated. The development of UC during chemotherapy is very rare and only a few case reports have been published. Although adverse events are rare, it is very important to assess the colitis precisely by performing a colonoscopy when protracted abdominal pain is experienced by the patient, along with diarrhoea or bloody stool during chemotherapy.

Introduction
Cytotoxic chemotherapy can cause various adverse effects involving the mucosa of the gastrointestinal tract. Ischaemic and pseudomembranous enterocolitis are well-known cytotoxic drug-induced enterocolitis [1,2]. Although drug-induced enterocolitis is a common phenomenon, ulcerative colitis (UC) is a very rare condition and only a few cases have been reported previously [3,4].

Here, we discuss a case of acute onset UC during chemoradiotherapy in a patient with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

Case Report
A 46-year-old male patient with an abnormal chest shadow was referred to our hospital. He had no obvious history of gastrointestinal diseases. Positron emission tomography-computed tomography (PET-CT) studies revealed a high uptake of fluorodeoxyglucose (FDG) in the small nodules of the right upper lobe, and bilateral mediastinal and right hilar lymphadenopathy (Fig. 1A, B). Specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS TBNA) of the mediastinal lymph node showed adenocarcinoma harbouring the ALK fusion gene (Fig. 1C–E). The clinical stage of his carcinoma was T1aN3M0 and stage IIIB. Concurrent chemoradiotherapy was selected for his initial therapy. After two cycles of cisplatin and vinorelbine administration, he experienced persistent diarrhoea and anorexia. Findings of the colonoscopy revealed a pancolitis type of UC. After discontinuation of chemotherapy, oral administration of mesalazine was initiated. The development of UC during chemotherapy is very rare and only a few case reports have been published. Although adverse events are rare, it is very important to assess the colitis precisely by performing a colonoscopy when protracted abdominal pain is experienced by the patient, along with diarrhoea or bloody stool during chemotherapy.
infiltration of inflammatory cells (Fig. 2E). He was diagnosed clinically and pathologically with UC. Although radiotherapy was continued, concurrent chemotherapy was discontinued after he was diagnosed with UC. The oral administration of mesalazine was initiated. After 2 months of administration of mesalazine, his digestive symptoms remitted and a second colonoscopy revealed that his UC improved. At the time of UC remission, his tumour slightly increased in size. Because his tumour harboured the ALK fusion gene, we administered an oral ALK inhibitor, alectinib as a second line therapy. We started with 300 mg/day of alectinib for the first 2 weeks and then dosed up to 600 mg/day. Administration of 600 mg/day has been effective in maintaining a response after the tumour recurrence.

Discussion

Chemotherapy-induced colitis is common with use of cytotoxic anticancer agents including fluoropyrimidines, irinotecan, methotrexate, docetaxel, vinorelbine and cisplatin [1,2]. Vinorelbine is also known to have venous toxicity and often causes cutaneous ulcers. Although various mechanisms are proposed for chemotherapy-induced colitis, including increased intestinal permeability, early onset anticholinergic effects and mesenteric vascular insufficiency, precise mechanisms are different for every drug.

The colitis in patients receiving chemotherapeutic agents is usually divided into three types including: neutropenic colitis, ischaemic colitis and *C. difficile*-associated colitis [2]. In our case, there was no evidence of compromised neutropenic status during chemoradiotherapy. After diarrhoea occurred, we confirmed the negative results of the *C. difficile* toxin and culture. A high possibility of ischaemic colitis remained. We also obtained typical images of UC during the colonoscopy and the pathology of the intestinal mucosa indicated evidence of UC. UC as an adverse effect of cytotoxic chemotherapy is a very rare condition. Previously, only two case reports have demonstrated UC during cytotoxic chemotherapy. One case was a patient with lung cancer whose UC was induced by bevacizumab therapy and the other case was a patient with breast cancer whose UC was induced by the therapy of a combination of capecitabine and trastuzumab [3,4].

Although precise mechanisms underlying the causes of UC are unknown, some mechanisms were speculated. In
patients receiving bevacizumab, anti-angiogenesis activity of bevacizumab may have played an important role [4]. Previously, therapy with a combination of docetaxel and vinorelbine for breast cancer was associated with exacerbation of intestinal toxicity [1]. In the present case, we also used cisplatin in addition to vinorelbine, and therefore, additive toxicity may have been induced. Intestinal mucosa vasculopathy associated with vinorelbine might affect the development of UC.

Although our patient did not have a colonoscopy before concurrent chemoradiotherapy, UC likely did not exist before the treatment for the following reasons. First, our patient had no history of abdominal pains, diarrhoea or bloody stool. A faecal occult blood test was also negative before the treatment. Because the UC of this patient was a pancolitis type, the patient was unlikely to remain free of symptoms. Second, baseline PET-CT apparently showed no FDG uptake in bowel, which can support the notion that there was no pre-existing UC. Third, previous reports suggested that cytotoxic chemotherapy can remit activity of UC [5]. If UC existed before the diagnosis of lung cancer, chemotherapy would have inhibited the symptoms.

In conclusion, we encountered a rare case of UC during chemoradiotherapy. Although this rare complication occurred in a patient with a rare type of lung cancer with ALK translocation, it is very important to assess the patient to determine the type of colitis by colonoscopy when the patient experiences protracted abdominal pain, diarrhoea or bloody stool during chemotherapy.

Acknowledgments
We thank Drs. Osamu Kanai, Misato Okamura and Koichi Nakatani for their helpful support in patient care.

Disclosure Statement
Appropriate written informed consent was obtained for publication of this case report and accompanying images.

References
1. Ibrahim NK, Sahin AA, Dubrow RA, et al. 2000. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200):281–283.
2. Zeino Z, Sisson G, and Bjarnason I. 2010. Adverse effects of drugs on small intestine and colon. Best Pract. Res. Clin. Gastroenterol. 24(2):133–141.

3. Katada Y, Nakano M, Ishii Y, et al. 2011. A case of ulcerative colitis associated with chemotherapy for breast cancer. Prog. Dig. Endosc. 79(2):96–97 [In Japanese, English abstract available].

4. Tanaka M, Ishii H, Azuma K, et al. 2015. Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab. Invest. New Drugs 33(5, 5):1133.

5. Axelrad JE, Fowler SA, Friedman S, et al. 2012. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin. Gastroenterol. Hepatol. 10(9):1021–1027.e1.